Table 1 Detailed information of the included studies
Study and year | Type | Country | Company | Medicine | Intervention | Follow-up, weeks | Group | Subgroup§ | Outcomes‡ |
|---|---|---|---|---|---|---|---|---|---|
Fleischmann 2019 [51] | RCT | USA | AbbVie Inc | ABT981(IL-1 antibody) | SC, once every 2 weeks, lasting for 50 weeks | 52 | 25 mg 100 mg 200 mg | Subgroup 1 Subgroup 2 Subgroup 3 | ①②⑥ |
Cohen 2011 [52] | RCT | USA | Amgen Inc | AMG 108 (IL-1 Ras) | SC, once every 4 weeks, lasting for 12 weeks IV, once every 4 weeks, lasting for 12 weeks SC, once every 4 weeks, lasting for 12 weeks | 12 | 75 mg 300 mg 100 mg 300 mg 300 mg | Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4 Subgroup5 | ⑥ |
Baltzer 2009 [53] | Multicentre enter RCT | Germany | NA | Orthokine† (IL-1 Ras) | IA, twice a week, lasting for 3 weeks | 26 | NA | Subgroup 1 | ①②⑤⑥ |
Yang 2008 [54] | RCT | Netherlands | NA | Orthokine† (IL-1 Ras) | IA on days 0, 3, 7, 10, 14 and 21 | 48 | NA | Subgroup 1 | ③④⑤ |
Wang 2017 [55] | RCT | USA | AbbVie Inc | ABT-981 (IL-1 antibody) | SC, once every 1 week, lasting for 8 weeks SC, once every 4 weeks, lasting for 12 weeks | 16.7 18.1 | 0.3 mg/kg 1 mg/kg 3 mg/kg 3 mg/kg | Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4 | ⑥ |
Chevalier 2009 [56] | Multicentre enter RCT | France | Amgen Inc | Anakinra (IL-1 Ras) | Single IA | 12 | 50 mg 150 mg | Subgroup 1 Subgroup 2 | ⑤⑥ |
Kosloski 2016 [57] | RCT | USA | AbbVie Inc | ABT-981(IL-1 antibody) | SC, once every 2 weeks, lasting for 8 weeks SC, once every 4 weeks, lasting for 12 weeks | 18 | 0.3 mg/kg 1 mg/kg 3 mg/kg 3 mg/kg | Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4 | ⑥ |
NCT01160822 2012[58] | RCT | USA | Novartis Inc | Canakinumab (IL-1 antibody) | Single IA Single IA of canakinumab + oral placebo twice a day (control group: placebo + placebo), lasting for 12 weeks | 18 | 150 mg 300 mg 600 mg 600 mg Canakinumab + placebo | Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4 | ⑥ |
Brahmachari 2009 [59] | RCT | India | NA | Diacerein(IL-1 inhibitor) | Oral, once a day for the first 10 days, 50 mg after meals, lasting for 8 weeks | 12 | NA | Subgroup 1 | ②⑤⑥ |
Pelletier 2000 [60] | Multicentre enter RCT | France | Les Laboratoires Negma | Diacerein(IL-1 inhibitor) | Oral twice a day for 16 weeks | 12 | 50 mg 100 mg 150 mg | Subgroup 1 Subgroup 2 Subgroup 3 | ①②⑤⑥ |
Pham 2004 [61] | Multicentre enter RCT | France | NA | Diacerein(IL-1 inhibitor) | Oral twice a day for 12 weeks | 48 | NA | Subgroup 1 | ⑤⑥ |
Pavelka 2007 [62] | Multicentre enter RCT | Czech | TRB Chemedica and Glynn Brothers Chemicals | Diacerein(IL-1 inhibitor) | Oral twice a day for 12 weeks | 24 | NA | Subgroup 1 | ②⑥ |